TY - JOUR
T1 - Early interim PET scan in Hodgkin lymphoma
T2 - where do we stand?
AU - Gallamini, Andrea
AU - Hutchings, Martin
AU - Avigdor, Abraham
AU - Polliack, Aaron
PY - 2008/4
Y1 - 2008/4
N2 - Positron emission tomography using [18F]-fluoro-2-deoxy-d-glucose (FDG-PET) is an important tool for staging and treatment response assessment in malignant lymphomas. In Hodgkin lymphoma (HL), FDG-PET precisely predicts the therapy response when performed very early during standard ABVD chemotherapy. However, it is unclear whether FDG-PET retains this role if therapy is changed as a consequence of the scan, or if performed during a more intensive chemotherapy regimen such as BEACOPPesc, which is used for HL. This brief review presents the up-to-date evidence for the use and interpretation of early interim FDG-PET in HL, including recent preliminary results on early interim FDG-PET during BEACOPPesc therapy.
AB - Positron emission tomography using [18F]-fluoro-2-deoxy-d-glucose (FDG-PET) is an important tool for staging and treatment response assessment in malignant lymphomas. In Hodgkin lymphoma (HL), FDG-PET precisely predicts the therapy response when performed very early during standard ABVD chemotherapy. However, it is unclear whether FDG-PET retains this role if therapy is changed as a consequence of the scan, or if performed during a more intensive chemotherapy regimen such as BEACOPPesc, which is used for HL. This brief review presents the up-to-date evidence for the use and interpretation of early interim FDG-PET in HL, including recent preliminary results on early interim FDG-PET during BEACOPPesc therapy.
KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
KW - Fluorodeoxyglucose F18
KW - Hodgkin Disease/diagnosis
KW - Humans
KW - Positron-Emission Tomography/methods
U2 - 10.1080/10428190801888704
DO - 10.1080/10428190801888704
M3 - Review
C2 - 18398732
SN - 1042-8194
VL - 49
SP - 659
EP - 662
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 4
ER -